Somatropin - Pacira

Drug Profile

Somatropin - Pacira

Alternative Names: hGH - Pacira; hGH-DepoFoam®; Human growth hormone - Pacira; Human growth hormone-DepoFoam®

Latest Information Update: 03 May 2012

Price : $50

At a glance

  • Originator SkyePharma Inc
  • Developer Pacira Pharmaceuticals; SkyePharma Sweden
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Growth disorders

Most Recent Events

  • 16 Jul 2013 Biomarkers information updated
  • 03 May 2012 Discontinued - Phase-I for Growth disorders in Europe (SC)
  • 03 May 2012 Discontinued - Phase-I for Growth disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top